Back To Schedule
Tuesday, March 14 • 4:00pm - 4:45pm
Panel: Advance your Assets: Strategies for Negotiating and Evaluating Platform Deals

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Feedback form is now closed.
  • Identify trends, new modalities and enabling technologies including drug discovery platforms, gene editing, AI and digital health
  • Understanding the differences between platform vs. product deals including valuation and deal structures
  • Defining success for these deals and creating collaborations that will benefit both parties

avatar for Ekaterine (Eka) Kortkhonjia

Ekaterine (Eka) Kortkhonjia

Sr. Director, Early Innovation Partnering, Johnson & Johnson
Eka is a Senior Director of Early Innovation Partnering at Johnson and Johnson. In this role Eka is responsible for identification, diligence and strategic transactions for data science opportunities across therapeutic areas from discovery through commercial execution. Eka joined... Read More →

avatar for Anne Stevens

Anne Stevens

VP of Business Development, AbCellera
Ms. Stevens is currently the Head of Business Partnering at AbCellera Biologics Inc., as well as a Director for Aequus Pharmaceuticals and the LifesciencesBC organization. Ms Stevens was previously the Chief Operating Officer of Aequus Pharmaceuticals, a specialty pharmaceutical company... Read More →
avatar for Michelle Chen

Michelle Chen

Chief Business Officer, Insilico Medicine
Michelle Chen is the Chief Business Officer of Insilico Medicine, a leader in the AI-powered drug discovery and development company.She is responsible for company’s strategies, business and corporate development, revenue growth and US operations. As a biotech executive, Michelle... Read More →
avatar for Scott Saywell

Scott Saywell

Chief Business Officer, Herophilus
Scott Saywell is the Chief Business Officer at Herophilus, a San Francisco-based neurotherapeutics company focused on curing brain diseases with its proprietary technology platform based on in vitro human tissue models.  Scott has over twenty-five years of experience in the biotech... Read More →
avatar for Jeff Landau

Jeff Landau

Chief Business Officer, CytomX Therapeutics
Jeff Landau is currently SVP, Chief Business Officer and Head of Strategy at CytomX Therapeutics (www.cytomx.com) where he leads BD&L, Corporate Strategy, Alliance and Program Management and New Product Planning and has recently closed platform deals with Regeneron and Moderna. Mr. Landau has over 20 years of biopharmaceutical experience in corporate development, corporate strategy, sales and new... Read More →

Tuesday March 14, 2023 4:00pm - 4:45pm PDT
Hyatt Centric Fisherman's Wharf San Francisco